P413: THE POTENTIAL USE OF AN ORAL HYPOMETHYLATING AGENT, OR-2100, AS A COMBINATION THERAPY FOR MYELOID MALIGNANCIES

• K. Kamachi,
• H. Ureshino,
• K. Kawasoe,
• N. Yoshida-Sakai,
• Y. Yamamoto,
• Y. Fukuda-Kurahashi,
• Y. Kurahashi,
• T. Watanabe,
• S. Kimura

Affiliations

K. Kamachi

1 Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine

H. Ureshino

1 Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine

K. Kawasoe

1 Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine

N. Yoshida-Sakai

1 Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine

Y. Yamamoto

1 Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine

Y. Fukuda-Kurahashi

2 Department of Drug Discovery and Biomedical Sciences, Saga university, Saga

Y. Kurahashi

1 Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine

T. Watanabe

2 Department of Drug Discovery and Biomedical Sciences, Saga university, Saga

S. Kimura

1 Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine